# 5-FU, Aflibercept, and Radiation (RT) for Preoperative and Postoperative Patients With Stage II/III Rectal Cancer

> **NCT01749956** · PHASE2 · COMPLETED · sponsor: **SCRI Development Innovations, LLC** · enrollment: 39 (actual)

## Conditions studied

- Rectal Cancer

## Interventions

- **RADIATION:** Radiation
- **DRUG:** Aflibercept
- **PROCEDURE:** Surgery
- **DRUG:** FOLFOX6

## Key facts

- **NCT ID:** NCT01749956
- **Lead sponsor:** SCRI Development Innovations, LLC
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-01
- **Primary completion:** 2015-09
- **Final completion:** 2015-09
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2017-02-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01749956

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01749956, "5-FU, Aflibercept, and Radiation (RT) for Preoperative and Postoperative Patients With Stage II/III Rectal Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01749956. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*